The currently approved kinase inhibitors for therapeutic uses and a number of kinase inhibitors that are undergoing clinical trials are directed toward the adenosine triphosphate (ATP) binding site of protein kinases. The 5′-fluorosulfonylbenzoyl 5′adenosine (FSBA) is an ATP-affinity reagent that covalently modifies a conserved lysine present in the nucleotide-binding site of most kinases. The authors have developed a liquid chromatography/mass spectrometry-based method to monitor binding of ATP competitive protein kinase inhibitors using FSBA as a nonselective activity-based probe for protein kinases. Their method provides a general, rapid, and reproducible means to screen and validate selective ATP competitive inhibitors of protein kinases. (Journal of Biomolecular Screening 2005:447-455) 
INTRODUCTION
P ROTEIN KINASES PLAY IMPORTANT ROLES in signal transduction pathways and in many cell regulatory processes such as cell division and differentiation, development, oncogenesis, cell survival, and apoptosis. Based on the functional classification of human genes, more than 500, which comprise~2% of the total human genes, have been identified to encode protein kinases. 1 Because many protein kinases are regulators or effectors of pharmacologically relevant proteins, it is not surprising that protein kinases have emerged as attractive targets for the identification and development of novel therapeutic agents for many disease indications. [2] [3] [4] The majority of the small-molecule kinase inhibitors studied so far bind to the Mg-adenosine triphosphate (ATP) complex binding pocket of protein kinases, and considerable progress has been made toward making these inhibitors potent and selective. [4] [5] [6] Currently, 3 kinase inhibitors are approved for the treatment of cancer: 3, 6 Gleevec (STI1571), Fasudil (Y-27632), and Iressa (ZD 1839). These 3 inhibitors and numerous inhibitors that are currently in clinical trials are directed toward the ATP binding site. Together, these studies demonstrate the promise of protein kinases as drug targets and that inhibitors competitive with ATP can be useful for the treatment of human diseases.
The 5′-fluorosulfonylbenzoyl 5′-adenosine (FSBA) is an ATPaffinity reagent that covalently modifies the nucleotide-binding sites of a variety of protein kinases. [7] [8] [9] As depicted in Figure 1 , FSBA is structurally similar to ATP, except for the presence of the flurosulfonylbenzoyl moiety in place of the phosphoryl groups of ATP. 9, 10 Peptide mass fingerprinting studies carried out on a panel of protein kinases have shown that FSBA binds irreversibly to the ε amino group of a conserved lysine residue located in the ATP binding site. 7, 11 The 14 C-FSBA reagent 12 and FSBA-specific antibodies 13, 14 have been used to identify and characterize protein kinases from cell lysates. Recently, Maly and coworkers 15 described the synthesis of modified FSBA, in which the aryl sulfonyl fluoride moiety of FSBA was replaced with an O-phthaldialdehyde, for use in identification of a kinase-substrate pair.
The liquid chromatography/mass spectrometry (LC/MS) technique has been valuable for monitoring the covalent modification of natural and recombinantly expressed proteins. 16 These techniques have also been routinely used in drug metabolism and pharmacokinetics studies, but their use as screening tools has not been widely explored. Given that FSBA binds covalently in the ATP binding pocket of protein kinases, we reasoned that LC/MS would also have utility in screening ATP competitive protein kinase inhibitors. Using purified recombinant kinases and FSBA as an activity-based probe (ABP), we demonstrate here that FSBA labeling monitored by LC/MS provides a general, rapid, and reproducible method to screen and validate selective ATP competitive inhibitors of protein kinases in real time.
MATERIALS AND METHODS

Reagents
Purified protein kinases used in the present studies were the baculovirus-expressed kinase domain of the transforming growth factor (TGF)-β type I receptor, activin receptor-like kinase (ALK5) 17 (obtained from Ruth Lehr, GlaxoSmithKline), and fulllength CDK2 1 8 (obtained from Dr. Warren Rocque, GlaxoSmithKline). The molecular weights of purified ALK5 and CDK2 based on their primary amino acid sequences are 34,974 Da and 33,972 Da, respectively. The purity of both proteins was >95%. 14 C-labeled FSBA was obtained from PerkinElmer Life Sciences. FSBA, staurosporine, and myoglobin were purchased from Sigma. SB-431542, 17 an ALK5-inhibitor, was synthesized at GlaxoSmithKline. Stock solutions of FSBA (1 mM), staurosporine (2 mM), and SB-431542 (10 mM) were prepared in 50% DMSO. Final concentration of DMSO in all experiments was less than 2.5%.
Autoradiography
Autoradiography on 14 C-FSBA-labeled protein kinases was carried out as described. 9, 12 Purified kinases (1-10 µg) were incubated with 20 to 40 µM 14 C-FSBA (specific activity, 40 mCi/ mmole) for 1 h at room temperature, and the samples were subjected to autoradiography. Equivalent amounts of the samples were also subjected to SDS-PAGE for Coomassie blue staining. For ATP protection studies, purified proteins were incubated with 10 mM ATP, 50 mM MgCl 2 , and 20 µM 14 C-FSBA for 1 h at room temperature and then subjected to SDS-PAGE for autoradiography or Coomassie blue staining. The dried gels were exposed to X-ray film at -80°C for 10 to 15 days.
Liquid chromatography/mass spectrometry
LC/MS studies were carried out on an automated singlechannel LC/MS instrument as described. 16 The instrument components included an Alliance HT™ Waters 2790 Separations Module (Waters) with an autosampler, a Waters 2487 dual-wavelength detector, an LCT-ESI-TOF mass spectrometer (Micromass, UK), and a system control computer (Model AP200, Compaq, 500 MHz). The MS instrument was calibrated with NaI/CsI solution directly infused into the ESI interface at a flow rate of 25 µL/min. Reverse-phase high-performance liquid chromatography (HPLC) parameters were essentially as described. 16 The flow rate was 0.3 to 0.5 mL/min for 1-or 2.1-mm i.d. columns. Ultraviolet (UV) absorbance was monitored at the 214-or 254-nm wavelength.
To follow the modification of proteins by FSBA (FSBA-HCl, Sigma), purified proteins (1-10 µg) were incubated with 10 µM FSBA (in 2.5% DMSO) at room temperature. For time-dependent modification studies, a 10-µL aliquot was removed at indicated times, mixed with 50 µL of 0.1% trifluoroacetic acid (TFA), and injected on LC/MS as described before. 16 For ATP protection experiments, purified kinases were coincubated with 10 µM FSBA and various amounts of ATP (as indicated in the figure legends) for 1 to 2 h at room temperature. For staurosporine protection experiments, purified protein kinases were coincubated with 10 µM FSBA with varied amounts of staurosporine (as described in the figure legends) for 1 to 2 h at room temperature. Samples were subjected to LC/MS as described above. All spectra were deconvoluted using the MaxEnt program, which is part of the MassLynx software (Micromass, UK), as described before. 16 Myoglobin was used as an external calibrant in all experiments.
Mapping of FSBA-labeling sites
Untreated and FSBA-treated ALK5 and CDK2 protein samples were reduced in 25 µM DTT followed by alkylation in 125 µM iodoacetamide. The proteins were digested in solution with trypsin at a trypsin/substrate ratio of 1:24 (w/w). The unfractionated digests were analyzed by MALDI-TOF mass spectrometry on a Micromass TofSpec SE instrument using 4-hydroxy cinnamic acid as the matrix.
RESULTS AND DISCUSSION
FSBA as an activity-based probe for protein kinases
Recently, several groups have described the use of chemical probes for functional proteomics and discovering potent and selective reversible inhibitors of enzymes in complex proteomes. 19, 20 The activity-based probes (ABPs) were targeted to distinct enzyme classes, which include serine hydrolases, [21] [22] [23] cysteine proteases, 24 and tyrosine phosphatases. 25 However, to the best of our knowledge, such probes have not yet been described for protein kinases.
FSBA (Fig. 1) is an alkylating ATP analog that can serve as a general affinity label for adenine nucleotide sites of dehydrogenases and kinases. 10, 12 Earlier studies have shown that FSBA covalently labels protein kinases by binding irreversibly to the ε amino group of a conserved ATP pocket lysine. 7-9 Therefore, we reasoned that FSBA could be used as an ABP for protein kinases.
To evaluate the reactivity of FSBA, we used the purified and well-characterized kinase domain of the transforming growth factor (TGF)-β type I receptor activin receptor-like kinase (ALK5) 17 and full-length CDK2. 18 First we incubated purified ALK5 (20 µg) and CDK2 (15 µg) with 14 C-labeled FSBA (50 µM, Amersham Biosciences) for 1 h at room temperature. The samples were either heated at 95°C or kept on ice for 10 min prior to the addition of 14 Because FSBA is an ATP analog, it is expected to compete with ATP for binding to the ATP pocket of protein kinases. Earlier studies showed that ATP competes with FSBA modification of many kinases. 7, 9, 14 To extend these studies to ALK5 and CDK2, the purified proteins were incubated for 1 h with~20 µM 14 C-FSBA, 10 mM ATP, and 50 mM MgCl 2 . The samples were subjected to SDS-PAGE as described above. The autoradiography ( Fig. 2B , left panel) and Coomassie blue staining of the gel (Fig. 2B , right panel) indicate that coincubation with ATP blocked binding of 14 C-FSBA to both kinases. These results, as predicted, confirm that that FSBA and ATP are competing for the same binding pocket in ALK5 and CDK2 proteins.
Mapping of FSBA-labeled sites of ALK5 and CDK2 kinases
Earlier studies have shown that FSBA specifically modifies a conserved lysine present in the ATP pocket of most protein kin-ases. The kinases used in FSBA labeling studies included cAMPdependent protein kinases, 7,11 epidermal growth factor receptor kinase, 26 P38γ, and phosphotidylinositol 4-kinase 230. 27 To evaluate if this is also the case with ALK5 and CDK2, we subjected unmodified and FSBA-modified ALK5 and CDK2 proteins for sequence analysis, as described under Materials and Methods.
The MALDI spectra of the FSBA-treated samples contained ions whose m/z values were consistent with the predicted masses for tryptic peptides containing the FSBA-modified lysine residue conserved in all protein kinase domains (not shown). These peptides were absent in the spectra of the untreated proteins. The modified peptides were sequenced on a Micromass QTOF mass spectrometer by full-time liquid chromatography/tandem mass spectrometry (LC/MS/MS) of the doubly charged precursor for each peptide. These spectra were consistent with the peptides GEEVAVK*IFSSR (ALK5) and LTGEVVALK*K (CDK2), where K* is the lysine modified by FSBA. The lysine (K) in boldface denotes the consensus site for the lysine residue involved in ATP binding (B. Zhao, GlaxoSmithKline, personal communication, 2002). These results confirm that under the experimental conditions employed, similar to the other kinases, FSBA reacts specifically with the nucleophilic group of conserved lysine residue in CDK2 and ALK5 kinase.
Together, the heat denaturation, ATP protection, and peptide mass-mapping results presented here strongly suggest that FSBA has potential to be an activity-based probe for evaluating protein kinase inhibitors. Because FSBA reacts with a panel of protein kinases by binding to the ATP binding site in the protein, and most of the protein kinase inhibitors are ATP competitors, we reasoned that FSBA could be used as an activity-based probe for screening ATP competitive inhibitors of protein kinases. Although the radioactive form of FSBA, which is commercially available, can be used for such studies, its detection by fluorography required several days to weeks (personal observations). Because FSBA modification of kinases is covalent, we explored the use of the LC/MS technique 16 as an alternative to autoradiography using a commercially available untagged version of FSBA.
FSBA labeling of ALK5 and CDK2 analyzed by LC/MS
To follow the FSBA modification of protein kinases by LC/MS, we first performed a time-dependent reaction in which purified ALK5 was incubated with FSBA (Sigma) at room temperature. Then, 10-µL aliquots of incubation mixture, taken out at defined (5, 10, 20, 30, and 60 min) time intervals, were injected onto LC/ MS as described in Materials and Methods. As described by Feng and coworkers, 16 molecular weights of proteins were calculated from multiply charged ion series, and MaxEnt, a deconvolution program, which is part of the Mass Lynx software, was used to provide a zero-charge MaxEnt spectrum from the unprocessed raw data. Deconvolution parameters were identical for myoglobin (16, 951 Da) standard and proteins used in the present study to ensure calculation uniformity. 
LC/MS-Based Method for Selecting ATP Competitive Kinase Inhibitors
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As shown in Figure 3A , the deconvoluted ESI mass spectrum of purified ALK5 gave a molecular mass of 34,974 Da, expected for the baculovirus-expressed ALK5 protein. 17 Incubation in the presence of FSBA caused a shift in molecular mass to 35,407 Da in a time-dependent (5-60 min) manner (Fig. 3A) . By 60 min, the parent peak was completely converted to the 35,407 Da molecular mass species, with increased mass of 433 Da. Likewise, the covalent modification of CDK2 was completed (from 33,972 to 34,405 Da) by 1 h (Fig. 3B) , as seen by the corresponding increase (433 Da) in the molecular mass of the FSBA-treated CDK2 protein. These and the above-described peptide mass-mapping results indicate that FSBA covalently labels ALK5 and CDK2 proteins at a single site (i.e., conserved lysine in the ATP binding pocket) under the experimental conditions used in these studies.
The difference in the unmodified and FSBA-modified forms of each of the kinases tested accounts for the presence of the cova- lently attached sulfonylbenzoyl adenosine moiety with the removal of the fluorine atom. These results are analogous to the affinity labeling of P38γ by FSBA, as reported by Fox and coworkers. 9 Similar to the autoradiography experiment, denatured ALK5 and CDK2 proteins did not react with FSBA, nor did FSBA modify trypsin or BSA (not shown). Together, these results further confirmed FSBA's selective reactivity to ATP-requiring protein kinases. Importantly, because the covalent labeling, which occurs at the conserved lysine in the ATP binding pocket, can be monitored in real time and eliminates the need for the radioactive form of FSBA for detection, the LC/MS technique offers considerable advantage over the autoradiography method.
ATP competes with FSBA modification of protein kinases
Our autoradiography studies showed that ATP competes with the FSBA modification of ALK5 kinase. To follow the ATP protection effects by LC/MS, the purified ALK5 and CDK2 kinases were coincubated independently in the presence of FSBA and varying amounts of ATP, as described in Materials and Methods. As shown in Figure 4 , ATP protected covalent modification of both ALK5 (Fig. 4A ) and CDK2 (Fig. 4B ) by FSBA in a concentrationdependent manner. Interestingly, under the experimental conditions used, although most of the covalent modification of ALK5 was inhibited in the presence of 0.5 mM ATP, 5 mM ATP was required to obtain nearly complete protection of CDK2. These stud-FIG. 4. Adenosine triphosphate (ATP) competes with binding of 5′-fluorosulfonylbenzoyl 5′-adenosine (FSBA) to ALK5 (A) and CDK2 (B). Purified ALK5 (10 µg) or CDK2 (10 µg) was incubated with FSBA (10 µM) and varying amounts of ATP (50 µM to 10 mM) at room temperature. Then, 10-µL aliquots of samples were subjected to liquid chromatography/mass spectrometry (LC/MS), as described in Materials and Methods. Arrows indicate corrected molecular weights based on myoglobin as standard. ies suggest that the affinity of ATP for ALK5 is significantly higher than that for CDK2. Alternatively, FSBA binds more tightly to CDK2 than ALK5 in these conditions. On the basis of these data, we find that LC/MS will be a good technique to evaluate relative binding affinities of ATP and FSBA for various protein kinases.
Effects of ATP competitor kinase inhibitors
The ATP protection experiments suggest that ATP competitor small-molecule protein kinase inhibitors, which also encompass the ATP binding pocket, would also prevent covalent modification of kinases by FSBA. Staurosporine, a microbial alkaloid, is a potent but nonspecific protein kinase inhibitor. 4, 28 It inhibits a number of kinases, including CDK2, 28 Chk1, 29 and ALK5 kinase (N. Laping, unpublished results), with IC 50 values in the nanomolar range. Crystal structures of CDK2 and Chk1 kinases complexed with staurosporine have been reported. 28, 29 In both structures, staurosporine was shown to bind in the ATP binding cleft with the tetrahydropyran ring in a boat conformation.
To evaluate the protective effects of staurosporine, purified ALK5 and CDK2 proteins were first coincubated with FSBA and increasing amounts of staurosporine (0.1-10 µM). Next, the samples were analyzed by LC/MS, as described in Materials and Methods. Figure 5A ,B shows the LC/MS profiles of ALK5 and CDK2 tested in the presence of FSBA and staurosporine. In each case, staurosporine abrogated FSBA labeling in a concentrationdependent manner, and the modification was completely blocked by the addition of 10 µM staurosporine.
The data generated with staurosporine suggested that the LC/ MS-based approach could be extended to screen selective ATP competitive protein kinase inhibitors. SB-431542 is a selective ATP competitive inhibitor of ALK5, with an IC 50 of 94 nM. 17, 30 SB-431542, however, does not inhibit CDK2 (N. Laping, unpublished results). Because SB-431542 is an ATP competitive ALK5 inhibitor, like staurosporine, it should also compete with the binding of FSBA to ALK5 but not to CDK2. To confirm this, we incubated purified ALK5 and CDK2 in the presence of stoichiomteric amounts of FSBA and SB-431542 for 1 h. The samples were then subjected to LC/MS analysis, as described in Materials and Methods. Results in Figure 5C show that preincubation with 10 µM SB-432542 prevented binding of FSBA to ALK5 (left panel) but not to CDK2 (left panel). These results further validate that FSBA modification monitored by LC/MS can be used to screen and identify selective ATP competitive kinase inhibitors.
CONCLUSIONS
The work presented here and published by others strongly suggests that FSBA or its derivatives have potential to be an ABP for protein kinases. In the present study, we used autoradiography and LC/MS techniques to evaluate the utility of FSBA as an ABP for protein kinases. FSBA reacted with ALK5 and CDK2, two model kinases used in the present study, in a time-dependent manner. Us-ing MALDI and LC/MS/MS techniques, we also identified the sites of FSBA modification on ALK5 and CDK2. The modification was at a single site on the conserved lysine present in the ATP binding pockets of ALK5 and CDK2.
Importantly, our work further demonstrates that FSBA labeling monitored by LC/MS in real time can be used as a secondary screening method for the validation of selective ATP competitive protein kinase inhibitors. Compared to fluorography, which takes days to weeks for evaluation, LC/MS allows rapid-10 mindetection of the inhibitor screening. Furthermore, using an integrated, 10-pump, 8-channel, parallel LC/MS, 31 the technique will have capability to screen 50 to 100 compounds/day. Finally, this method can also be applied to other enzyme classes, including proteases 22, 24 and phosphatases, 25 to screen class-specific inhibitors.
